干扰素-α或高三尖杉酯碱作为获得T315I BCR-ABL突变的慢性髓性白血病患者的挽救治疗。 - Suppr

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

作者信息

de Lavallade Hugues, Khorashad Jamshid S, Davis Howard P, Milojkovic Dragana, Kaeda Jaspal S, Goldman John M, Apperley Jane F, Marin David

出版信息

Blood. 2007 Oct 1;110(7):2779-80. doi: 10.1182/blood-2007-06-094508.

DOI:10.1182/blood-2007-06-094508

PMID:17881650

Abstract

摘要

相似文献

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

Blood. 2007 Oct 1;110(7):2779-80. doi: 10.1182/blood-2007-06-094508.

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):394-9. doi: 10.3816/CLML.2010.n.073.

Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.

Blood. 2010 May 6;115(18):3852. doi: 10.1182/blood-2010-02-269233.

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

Leukemia. 2007 Oct;21(10):2204-6. doi: 10.1038/sj.leu.2404772. Epub 2007 May 31.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Expert Rev Hematol. 2016 May;9(5):419-24. doi: 10.1586/17474086.2016.1151351. Epub 2016 Apr 21.

Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.

Chin Med J (Engl). 2009 Jun 20;122(12):1413-7.

Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia.

Pharmacogenomics. 2016 Jul;17(10):1159-1163. doi: 10.2217/pgs-2016-0049. Epub 2016 Jun 27.

Treatment of myelogenous leukemia: current status and investigational options.

Blood. 1996 Apr 15;87(8):3069-81.

Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.

Drugs Today (Barc). 2013 Jul;49(7):447-56. doi: 10.1358/dot.2013.49.6.1980495.

引用本文的文献

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1+ clones in TKI-resistant CML.

EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21.

Cephalotaxus Alkaloids.

Alkaloids Chem Biol. 2017;78:205-352. doi: 10.1016/bs.alkal.2017.07.001. Epub 2017 Aug 16.

Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.

Tumour Biol. 2014 Jul;35(7):7187-93. doi: 10.1007/s13277-014-1926-9. Epub 2014 Apr 26.

Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):530-3. doi: 10.1016/j.clml.2013.03.017. Epub 2013 Jun 20.

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):584-91. doi: 10.1016/j.clml.2013.03.020. Epub 2013 Jun 17.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Haematologica. 2013 Oct;98(10):1510-6. doi: 10.3324/haematol.2012.080234. Epub 2013 May 28.

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.

Int J Hematol. 2012 Feb;95(2):209-13. doi: 10.1007/s12185-012-1005-1. Epub 2012 Jan 20.

Selection of therapy: rational decisions based on molecular events.

Hematol Oncol Clin North Am. 2011 Oct;25(5):1009-23, vi. doi: 10.1016/j.hoc.2011.09.006.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Blood. 2011 Nov 17;118(20):5697-700. doi: 10.1182/blood-2011-07-367326. Epub 2011 Sep 16.

Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.

Vaccine. 2010 Aug 23;28(37):6028-35. doi: 10.1016/j.vaccine.2010.06.085. Epub 2010 Jul 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.

作者信息

出版信息

相似文献

引用本文的文献